ArticleFrontiers in microbiology2025
Alterations in gut microbiota and metabolomic profiles in acute stroke: insights into brain-gut axis dysregulation.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Microbiota, systemic immunity, and extracellular vesicles in stroke: peripheral nodes as therapeutic leverage points.Journal of neuroinflammation · 2026Review
- Risk of occult gastrointestinal bleeding with increased gutFrontiers in neuroscience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Acute stroke (AS) is a major public health issue globally, exhibiting high morbidity, disability rate, and mortality. Emerging research has demonstrated the critical roles of gut microbiota and its metabolites in pathogenesis, recovery, and prognosis of AS. Methods: In this study, we investigated alterations in gut microbiota composition and metabolomic profiles in AS patients using 16S rRNA sequencing and untargeted liquid chromatography-mass spectrometry (LC-MS) metabolomics technology. Results: The results revealed significant changes in gut microbiota diversity and community structure in AS patients compared with healthy controls. Notably, the abundance of anti-inflammatory microbiota was increased significantly, accompanied by elevated levels of certain metabolites, such as 6,9,12,15,18,21-tetracosahexaenoic acid and bufadienolide, while levels of urobilin and andrenid acid were significantly reduced. Network analysis further uncovered the significant diferences in microbiota-metabolite interactions between AS patients and healthy controls, indicating gut ecosystem disruption and functional dysfunction in AS. Discussion: This study sheds light on the mechanisms of brain-gut axis in AS, suggesting potential microbial and metabolite biomarkers, thus providing valuable insights into AS prediction and treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.